NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Metric	Value
Current Market Cap	$109.77M
Last Price	$4.26
52-Week High	$3.84
52-Week Low	$1.62

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$4.26	+32.34%	2.61M
3
4
5

NRX Pharmaceuticals Inc. (NRXP) Market Capitalization

Market Cap Data

Get NRX Pharmaceuticals Inc. Data in Excel

More NRXP Financial Data